NCT02360514View on ClinicalTrials.gov

Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Infection
Interventions
DRUG

Hantavax injection

Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY